What is HC Wainwright's Forecast for AUPH Q1 Earnings?

Key Points

• Analysts at HC Wainwright predict that Aurinia Pharmaceuticals will report $0.18 earnings per share (EPS) for Q1 2026, maintaining a "Buy" rating with a price target of $17.00.
• Aurinia Pharmaceuticals recently reported Q1 earnings of $0.16 EPS, exceeding analyst expectations of $0.08, with revenues reaching $62.47 million.
• Institutional investors have shown increasing confidence in Aurinia, with several purchasing new stakes in the company during the second quarter, raising their ownership to 36.83%.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a research report issued on Wednesday, July 30th. HC Wainwright analyst A. He expects that the biotechnology company will earn $0.18 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Aurinia Pharmaceuticals' Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.18 EPS and Q4 2026 earnings at $0.14 EPS.

Separately, Royal Bank Of Canada increased their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday.

Aurinia Pharmaceuticals Stock Up 7.8%

Shares of Aurinia Pharmaceuticals stock traded up $0.82 during trading hours on Thursday, hitting $11.31. 3,212,160 shares of the company's stock traded hands, compared to its average volume of 1,549,689. The stock has a 50 day simple moving average of $8.35 and a 200-day simple moving average of $8.14. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The company has a market cap of $1.49 billion, a PE ratio of 26.24 and a beta of 1.23. Aurinia Pharmaceuticals has a twelve month low of $5.20 and a twelve month high of $11.47.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The firm had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Large investors have recently made changes to their positions in the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at approximately $925,000. Nordea Investment Management AB raised its holdings in Aurinia Pharmaceuticals by 1.5% during the second quarter. Nordea Investment Management AB now owns 355,000 shares of the biotechnology company's stock worth $3,117,000 after purchasing an additional 5,400 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in Aurinia Pharmaceuticals during the second quarter worth approximately $92,000. Concurrent Investment Advisors LLC bought a new stake in Aurinia Pharmaceuticals during the second quarter worth approximately $238,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Aurinia Pharmaceuticals during the second quarter worth approximately $282,000. Institutional investors and hedge funds own 36.83% of the company's stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.